160 Neuroendocrine Tumor (NET) Clinical Trials Recruiting Now (May 2026): Carcinoid, GEP-NET, Lutathera, Actinium-225 PRRT (ACTION-1), DLL3 TCE (TARLANEC), Paltusotine, SSA
Last updated: May 28, 2026
Current Clinical Trial Landscape
Neuroendocrine tumors (NETs) include:
- GEP-NETs — gastroenteropancreatic (pancreas, small bowel, stomach)
- Carcinoid tumors — lung, GI tract
- Pheochromocytoma/paraganglioma
Active research areas in 2026:
- PRRT / Lutetium-177 combinations (45 trials)
- Somatostatin analogs (39 trials)
- Checkpoint inhibitors (176 trials)
- mTOR inhibitors (11 trials)
Standard of care: Somatostatin analogs (octreotide, lanreotide) for symptom control. PRRT (Lutathera) for progressive somatostatin receptor-positive tumors. Everolimus or sunitinib for progressive disease.
Recruiting Trials by Treatment Setting
First-Line / Newly Diagnosed
For previously untreated advanced NETs:
- Somatostatin analogs: Standard first-line for well-differentiated NETs
- PRRT in first-line:
- NCT06784752 - NETTER-3: 177Lu-DOTATATE in Grade 1-2 GEP-NETs (Phase 3, Novartis)
Second-Line / Progressive Disease
After progression on somatostatin analogs:
- PRRT (next-gen alpha-emitter + Lutathera combinations):
- NCT05477576 - ACTION-1: RYZ101 (actinium-225-DOTATATE, alpha-emitter PRRT) vs standard of care in inoperable SSTR-positive well-differentiated NETs (Phase 3, RayzeBio). First Phase 3 of an alpha-emitter PRRT in NETs — potentially deeper tumor kill than Lutathera's beta-emitter physics.
- NCT05687123 - Lutathera + Sunitinib in pancreatic NETs (Phase 1)
- NCT07185672 - PReCedeNT: PRRT vs PRRT + chemotherapy in GEP-NET (Phase 3, Tata Memorial Hospital)
- Targeted therapy:
- NCT06943755 - STELLAR-311: zanzalintinib vs everolimus in advanced NETs (Phase 2/3, Exelixis)
- T-cell engagers (novel mechanism in NET):
- NCT06937905 - TARLANEC: tarlatamab (DLL3-targeted bispecific T-cell engager) vs standard-of-care chemotherapy in pre-treated advanced NETs (Phase 3, Intergroupe Francophone). Tarlatamab is currently approved for ES-SCLC; this trial tests it in DLL3-positive NETs — first DLL3 TCE Phase 3 outside lung cancer.
- Carcinoid syndrome / symptom control:
- NCT07087054 - CAREFNDR: paltusotine (oral once-daily SSA) for carcinoid syndrome control (Phase 3, Crinetics Pharmaceuticals). Tests whether an oral SSA can replace monthly injection lanreotide/octreotide for carcinoid-syndrome symptom control.
Surgery Combinations
Trials by Treatment Approach
PRRT / Radioligand Therapy (Lutetium-177 + Actinium-225, 45+ trials)
Peptide receptor radionuclide therapy targets somatostatin receptors (SSTR2/5). Lutathera (177Lu-DOTATATE, beta-emitter) is FDA-approved; RYZ101 (225Ac-DOTATATE, alpha-emitter) is in Phase 3. Alpha-emitters deliver concentrated cytotoxicity per decay (~50-100 μm range, much shorter than beta) and may overcome PRRT resistance. View all →
- NCT05477576 - ACTION-1: RYZ101 (225Ac-DOTATATE alpha-emitter) vs SOC in SSTR+ well-differentiated NETs (Phase 3, RayzeBio)
- NCT06784752 - NETTER-3: 177Lu-DOTATATE in Grade 1-2 GEP-NETs (Phase 3, Novartis)
- NCT07185672 - PReCedeNT: PRRT vs PRRT + chemotherapy in GEP-NET (Phase 3, Tata Memorial)
- NCT05687123 - Lutathera + sunitinib in pancreatic NETs (Phase 1)
- NCT06016855 - Surgical debulking before PRRT (Phase 4)
Somatostatin Analogs (39 trials)
Octreotide and lanreotide control hormone secretion and slow tumor growth. Trials explore higher doses and combinations. View all →
Targeted Therapy (mTOR, TKI)
Everolimus (mTOR inhibitor) and sunitinib (TKI) are approved for progressive NETs. Trials test new agents and combinations.
- NCT06943755 - STELLAR-311: zanzalintinib vs everolimus in advanced NETs (Phase 2/3, Exelixis)
View all mTOR/TKI trials →
Immunotherapy (176 trials)
Checkpoint inhibitors show modest activity in NETs; trials explore combinations to improve response. View all →
Trials by NET Subtype
Pancreatic NETs
GI / Carcinoid Tumors
GEP-NETs (General)
Frequently Asked Questions
How do I find neuroendocrine tumor clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched NET trials in minutes. The tool considers your tumor grade, Ki-67 index, primary site, and treatment history.
What neuroendocrine tumor trials are currently recruiting?
There are 160 recruiting interventional trials for neuroendocrine tumors in May 2026, including targeted therapies (STELLAR-311 zanzalintinib vs everolimus), PRRT both lutetium-177 (NETTER-3, PReCedeNT) and next-generation actinium-225 alpha-emitter (ACTION-1 RYZ101), DLL3 T-cell engager (TARLANEC tarlatamab), oral SSA for carcinoid syndrome (CAREFNDR paltusotine), immunotherapy, and novel agents for GEP-NETs, carcinoid, pancreatic NETs, and neuroendocrine carcinoma (NEC).
Find NET Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition and tumor type.
Find Matching Trials
